Compare ADMA Biologics Inc (ADMA) vs Twilio Inc (TWLO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Twilio Inc — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while Twilio Inc trades at $213.75 (market cap $32.17B). The key difference: Twilio Inc is far larger — about 15.1× ADMA Biologics Inc's market cap, and Twilio Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | TWLO | |
|---|---|---|
Market Cap | $2.13B | $32.17B |
Sector | Health | Technology |
52-Week High | $20.38 | $236.64 |
52-Week Low | $7.60 | $92.44 |
Enterprise Value | $2.20B | $30.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Twilio (TWLO) trades at $211.97, up 1.27% with bullish technical signals and strong analyst support. The stock shows improving fundamentals with revenue growth from $4.5B to $5.1B in 2025 and a return to profitability after years of losses. Recent earnings beats and AI-driven demand for cloud communications tools support positive momentum. Technical indicators show the stock trading near pivot point resistance at $210 with bullish moving average alignment.
Twilio presents a growth opportunity with margin expansion potential and AI adoption driving demand, though elevated valuation metrics (P/E 316.79) warrant caution. Key risks include competitive pressures in cloud communications and execution challenges in maintaining profitability growth. Analyst consensus remains strongly bullish with 75% buy ratings and $211.69 price target, suggesting balanced risk-reward near current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →
